Amphista Therapeutics Names New CEO and CMO as It Preps AML Drug for Clinical Trials
Event summary
- Louise Modis, Ph.D., promoted to CEO; Patrick Kelly, M.D., appointed CMO.
- AMX-883 IND application expected in April 2026, with clinical trials starting in H2 2026.
- SMARCA and TEAD programs advancing toward key inflection points.
- Amphista aims to shortlist best-in-class compounds for SMARCA2 and TEAD degraders later in 2026.
The big picture
Amphista’s leadership changes come as it transitions from R&D to clinical-stage development, a critical phase for biotech companies. The appointments of Modis and Kelly signal a focus on clinical execution, particularly in AML, where AMX-883 could differentiate itself. The company’s ability to sustain momentum across its pipeline will be key as it competes in the crowded targeted protein degradation space.
What we're watching
- Clinical Execution
- Whether AMX-883 can deliver on its potential as a karyotype-independent AML treatment.
- Pipeline Progression
- The pace at which SMARCA and TEAD programs advance toward candidate nomination.
- Leadership Impact
- How the new CEO and CMO will shape Amphista’s strategic direction and clinical strategy.
Related topics